Novo Nordisk A Revenue Growth Rates (NVO), Current and Historic Growth - CSIMarket
CSIMarket
 


Novo Nordisk A  (NYSE: NVO)
 

NVO's Revenue Growth by Quarter and Year

Novo Nordisk A's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NVO/growth
https://api.csimarket.com/api/v1/companies/NVO/fundamentals
https://api.csimarket.com/api/v1/companies/NVO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
NVO Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 12,214.05
1st Quarter March 15,165.90
FY 27,379.95

NVOs Annual Revenue
Novo Nordisk A's Revenue in the fiscal year 2025 $ 46,820.32 millions
Novo Nordisk A's Revenue in the fiscal year 2024 $ 42,125.93 millions
Novo Nordisk A's Revenue in the fiscal year 2023 $ 33,717.55 millions
Novo Nordisk A's Revenue in the fiscal year 2022 $ 25,053.80 millions
Novo Nordisk A's Revenue in the fiscal year 2021 $ 22,398.45 millions




NVO Revenue second quarter 2025 Y/Y Growth Comment
Novo Nordisk A reported Revenue growth of 4.55% year on year in the second quarter 2025, to $ 12,214.05 millions, this is lower than Novo Nordisk A's recent average Revenue surge of 106.15%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 100 other companies have achieved higher Revenue growth. While Novo Nordisk A' s Revenue increase of 4.55% ranks overall at the positon no. 1101 in the second quarter 2025.




NVO Revenue ( Y/Y Growth %) 2025
FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 4.55 %
1st Quarter March 37.57 %
FY   -

Financial Statements
Novo Nordisk A's second quarter 2025 Revenue $ 12,214.05 millions NVO's Income Statement
Novo Nordisk A's second quarter 2024 Revenue $ 11,682.43 millions Quarterly NVO's Income Statement


NVO Revenue (Quarter on Quarter Growth %)

2025
FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -19.46 %
1st Quarter March 22.55 %
FY (Year on Year)   -




Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #101
Healthcare Sector #230
Overall #1101

Revenue Y/Y Growth Statistics
High Average Low
761.28 % 106.15 % 3.18 %
(Dec 31 2024)   (Dec 31 2019)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #101
Healthcare Sector #230
Overall #1101
Revenue Y/Y Growth Statistics
High Average Low
761.28 % 106.15 % 3.18 %
(Dec 31 2024)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Novo Nordisk A's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
301.14 % 19.86 % -73.83 %
(Dec 31 2024)  


NVO's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Novo Nordisk A disclosed fall in Revenue from the first quarter by -19.46% to $ 12,214.05 millions, from $ 15,165.90 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Novo Nordisk A's Revenue growth quarter on quarter, overall rank is 4160.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #233
Healthcare Sector #624
Overall #4160
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #233
Healthcare Sector #624
Overall #4160
Revenue Q/Q Growth Statistics
High Average Low
301.14 % 19.86 % -73.83 %
(Dec 31 2024)  


NVO's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Novo Nordisk A disclosed fall in Revenue from the first quarter by -19.46% to $ 12,214.05 millions, from $ 15,165.90 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 232 other companies have achieved higher Revenue quarter on quarter growth. While Novo Nordisk A's Revenue growth quarter on quarter, overall rank is 4160.


Novo Nordisk A's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)
12 Months Ending (Dec 31 2024) 12 Months Ending (Dec 31 2023) 12 Months Ending (Dec 31 2022) 12 Months Ending (Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 46,820.32
Y / Y Revenue Growth (TTM) 11.14 %
Year on Year Revenue Growth Overall Ranking # 1101
Seqeuential Revenue Change (TTM) 11.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 1101


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Novo Nordisk A's cumulative twelve months Revenue were $ 46,820 millions, company would post below average annual Revenue growth of 11.14% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Novo Nordisk A's Revenue growth from the 15165.9% growth in Dec 31 2024.

In the Healthcare sector 229 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1101, from total ranking in previous quarter at 1645.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 101
Healthcare Sector # 230
Overall # 1101

Revenue TTM Y/Y Growth Statistics
High Average Low
761.28 %
106.15 %
3.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 101
Sector # 230
S&P 500 # 1101
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2025 period, Novo Nordisk A's cumulative twelve months Revenue were $ 46,820 millions, company would post below average annual Revenue growth of 3.18% year on year, if the fiscal year would end at Dec 31 2025.
A slow-down in the Novo Nordisk A's Revenue growth from the 15165.9% growth in Dec 31 2024.

In the Healthcare sector 229 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1101, from total ranking in previous quarter at 1645.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 101
Healthcare Sector # 230
Overall # 1101

Revenue TTM Y/Y Growth Statistics
High Average Low
761.28 %
106.15 %
3.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 101
Sector # 230
S&P 500 # 1101




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Puma Biotechnology Inc 7.75%$ 7.754 millions
Cryoport inc 7.74%$ 7.737 millions
Schrodinger Inc 7.54%$ 7.542 millions
Boston Scientific Corporation7.53%$ 7.528 millions
Agilon Health Inc 7.15%$ 7.151 millions
Tenet Healthcare Corp6.77%$ 6.773 millions
Henry Schein Inc 6.73%$ 6.728 millions
Collegium Pharmaceutical Inc 6.67%$ 6.668 millions
Mallinckrodt Plc6.62%$ 6.617 millions
Johnson and Johnson6.60%$ 6.600 millions
Prestige Consumer Healthcare Inc 6.57%$ 6.569 millions
Msa Safety Inc6.25%$ 6.252 millions
Pacira Biosciences inc 6.24%$ 6.240 millions
Globus Medical Inc 5.94%$ 5.940 millions
Labcorp Holdings Inc 5.78%$ 5.778 millions
Tandem Diabetes Care Inc 5.77%$ 5.768 millions
Bristol myers Squibb Company5.74%$ 5.738 millions
Haemonetics Corporation5.65%$ 5.646 millions
Progyny Inc 5.58%$ 5.584 millions
Cytek Biosciences Inc 5.57%$ 5.566 millions
Amphastar Pharmaceuticals Inc 5.44%$ 5.441 millions
Becton Dickinson And Company5.44%$ 5.438 millions
Bruker Corporation5.22%$ 5.220 millions
Davita Inc 5.17%$ 5.165 millions
Park Dental Partners Inc 5.10%$ 5.102 millions
Lumexa Imaging Holdings Inc 5.08%$ 5.076 millions
Merck and Co Inc 5.07%$ 5.068 millions
Cv Sciences Inc 4.96%$ 4.958 millions
Viatris Inc 4.88%$ 4.877 millions
Fulgent Genetics Inc 4.86%$ 4.855 millions


About Novo Nordisk A Revenue Growth Rates (NVO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novo Nordisk A S (CIK 353278).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000353278-26-000012
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novo Nordisk A S’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.